View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 24, 2021

Scynexis reports positive data from Phase III oral VVC treatment trial

Oral ibrexafungerp was found to be superior to placebo in the primary and all crucial secondary endpoints of the trial.

Scynexis has reported positive data from the Phase III VANISH-306 clinical trial of its new oral therapy, Brexafemme (Ibrexafungerp) to treat vulvovaginal candidiasis (VVC), a vaginal yeast infection caused due to Candida.

An antifungal licensed to treat VVC, Brexafemme works by hindering glucan synthase. It is fungicidal against Candida species and destroys fungal cells.

The international, multicentre, double-blind, randomised, placebo-controlled trial analysed the efficacy and safety of ibrexafungerp as against placebo in female subjects aged over 12 years with VVC.

Findings showed that ibrexafungerp demonstrated to be superior to placebo in the primary as well as all crucial secondary goals of the trial.

Nearly 63.3% of the subjects in the ibrexafungerp arm had substantially increased clinical cure rates as against 44% in the placebo arm, at the test-of-cure (TOC) day-ten visit.

Day-ten data also showed that ibrexafungerp outperformed placebo in terms of mycological eradication and clinical improvement.

Ibrexafungerp was found to be safe and well-tolerated in the trial with side effects observed to be gastrointestinal in nature and of mild to moderate severity.

Furthermore, the oral antifungal provided lasting clinical effect at day 25 visit with 73.9% in the ibrexafungerp group attaining a complete sign and symptom resolution.

Scynexis chief medical officer David Angulo said: “Ibrexafungerp is a first-in-class, one-day oral therapy that blocks glucan synthase, an enzyme critical for the maintenance of the fungal cell wall, and has shown in vitro fungicidal activity against multiple different Candida species strains, including those that are echinocandin and azole-resistant.”

The US Food and Drug Administration’s approval for Brexafemme to treat VVC is based on data from two Phase III trials, VANISH-303 and VANISH-306, of the VANISH development programme.

In January this year, Mycovia reported positive topline data from the Phase III ultraVIOLET trial of oteseconazole (VT1161), to treat people with recurrent vulvovaginal candidiasis (RVVC).

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy